Compare W W Grainger Inc (GWW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? W W Grainger Inc trades at $1,330.68 (market cap $62.41B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: W W Grainger Inc is far larger — about 8.3× Spyre Therapeutics Inc. Common Stock's market cap, and W W Grainger Inc pays a 0.75% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 26 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GWW | SYRE | |
|---|---|---|
Market Cap | $62.41B | $7.52B |
Volume | 284,715 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $1.40K | $108.92 |
52-Week Low | $918.18 | $22.18 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $64.62B | $6.52B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,325.10, up 1.41% today, with a bullish technical signal and strong fundamentals including a 47.92% ROE and 9.92% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a solid dividend as a Dividend King. Institutional buying and positive analyst coverage support the stock's momentum.
Outlook remains positive with a consensus price target of $1,310, though high valuation multiples and competitive pressures pose risks. Earnings growth and market share gains in industrial distribution are key drivers for continued upside.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
